Our results showed that the combination of gefitinib and BYL719 downregulated the phosphorylation levels of AKT in NSCLC cell lines carrying EGFR mutations and PIK3CA mutations/amplification. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.